Search

Your search keyword '"Becker, Jürgen C."' showing total 1,450 results
Start Over Author "Becker, Jürgen C."
1,450 results on '"Becker, Jürgen C."'

401. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline

Author

Stratigos, Alexander, primary, Garbe, Claus, additional, Lebbe, Celeste, additional, Malvehy, Josep, additional, del Marmol, Veronique, additional, Pehamberger, Hubert, additional, Peris, Ketty, additional, Becker, Jürgen C., additional, Zalaudek, Iris, additional, Saiag, Philippe, additional, Middleton, Mark R., additional, Bastholt, Lars, additional, Testori, Alessandro, additional, and Grob, Jean-Jacques, additional

Published
2015
Full Text
View/download PDF

403. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma

Author

Kim, Ellen J., primary, Kim, Youn H., additional, Rook, Alain H., additional, Lerner, Adam, additional, Duvic, Madeleine, additional, Reddy, Sunil, additional, Robak, Tadeusz, additional, Becker, Jürgen C., additional, Samtsov, Alexey, additional, McCulloch, William, additional, Waksman, Joel, additional, and Whittaker, Sean, additional

Published
2015
Full Text
View/download PDF

404. Photokatalytisch induzierter Zelltod von humanen Plattenepithelkarzinomzellen durch Zinkoxid Nanopartikel

Author

Hackenberg, Stephan, Scherzed, Agmal, Becker, Jürgen C., and Kleinsasser, Norbert

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Der Einsatz von Nanomaterialien in der medizinischen Diagnostik und Therapie ist etabliert. Einige Metalloxid-Nanopartikel (NP) wie Titandioxid (TiO2) oder Zinkoxid (ZnO) besitzen photokatalytische Eigenschaften. Ziel dieser Studie war die Beurteilung zytotoxischer Effekte durch die Behandlung von Karzinomzellen[for full text, please go to the a.m. URL], 81. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie

Published
2010

405. Ectopic expression of a novel CD22 splice-variant regulates survival and proliferation in malignant T cells from cutaneous T cell lymphoma (CTCL) patients

Author

Bagdonaite, Ieva, primary, Wandall, Hans H., additional, Litvinov, Ivan V., additional, Nastasi, Claudia, additional, Becker, Jürgen C., additional, Dabelsteen, Sally, additional, Geisler, Carsten, additional, Bonefeld, Charlotte M., additional, Zhang, Qian, additional, Wasik, Mariusz A., additional, Zhou, Youwen, additional, Sasseville, Denis, additional, Ødum, Niels, additional, and Woetmann, Anders, additional

Published
2015
Full Text
View/download PDF

406. Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer

Author

Hjortsø, Mads Duus, primary, Larsen, Stine Kiaer, additional, Kongsted, Per, additional, Met, Özcan, additional, Frøsig, Thomas Mørch, additional, Andersen, Gitte Holmen, additional, Ahmad, Shamaila Munir, additional, Svane, Inge Marie, additional, Becker, Jürgen C, additional, Straten, Per thor, additional, and Andersen, Mads Hald, additional

Published
2015
Full Text
View/download PDF

407. Exercise suppresses tumor growth through epinephrine- and IL-6-dependent mobilization and redistribution of NK cells

Author

Pedersen, Line, primary, Idorn, Manja, additional, Olofsson, Gitte, additional, Nookaew, Intawat, additional, Hansen, Rasmus, additional, Johannesen, Helle, additional, Becker, Jürgen C, additional, Lauenborg, Britt, additional, Pedersen, Katrine S, additional, Dethlefsen, Christine, additional, Nielsen, Jens B, additional, Gehl, Julie, additional, Pedersen, Bente, additional, thor Straten, Per, additional, and Hojman, Pernille, additional

Published
2015
Full Text
View/download PDF

408. Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma

Author

Paulson, Kelly G., primary, Tegeder, Andrew, additional, Willmes, Christoph, additional, Iyer, Jayasri G., additional, Afanasiev, Olga K., additional, Schrama, David, additional, Koba, Shinichi, additional, Thibodeau, Renee, additional, Nagase, Kotaro, additional, Simonson, William T., additional, Seo, Aaron, additional, Koelle, David M., additional, Madeleine, Margaret, additional, Bhatia, Shailender, additional, Nakajima, Hideki, additional, Sano, Shigetoshi, additional, Hardwick, James S., additional, Disis, Mary L., additional, Cleary, Michele A., additional, Becker, Jürgen C., additional, and Nghiem, Paul, additional

Published
2014
Full Text
View/download PDF

410. High-level expression of wild-type p53 in melanoma cells is frequently associated with inactivity in p53 reporter gene assays

Author

Houben, Roland, Hesbacher, Sonja, Schmid, Corinna P., Kauczok, Claudia S., Flohr, Ulrike, Haferkamp, Sebastian, Müller, Cornelia S. L., Schrama, David, Wischhusen, Jörg, and Becker, Jürgen C.

Subjects
Skin Neoplasms, Base Sequence, %22">Krebs , lcsh:R, Cell Cycle, DNA Mutational Analysis, Molecular Sequence Data, Hautkrebs, lcsh:Medicine, Genetic Techniques, Genes, Reporter, Cell Line, Tumor, Mutation, Molecular Cell Biology, Humans, lcsh:Q, ddc:610, Tumor Suppressor Protein p53, lcsh:Science, Melanoma, Biology, Research Article
Abstract

Background: Inactivation of the p53 pathway that controls cell cycle progression, apoptosis and senescence, has been proposed to occur in virtually all human tumors and p53 is the protein most frequently mutated in human cancer. However, the mutational status of p53 in melanoma is still controversial; to clarify this notion we analysed the largest series of melanoma samples reported to date. Methodology/Principal Findings: Immunohistochemical analysis of more than 180 melanoma specimens demonstrated that high levels of p53 are expressed in the vast majority of cases. Subsequent sequencing of the p53 exons 5–8, however, revealed only in one case the presence of a mutation. Nevertheless, by means of two different p53 reporter constructs we demonstrate transcriptional inactivity of wild type p53 in 6 out of 10 melanoma cell lines; the 4 other p53 wild type melanoma cell lines exhibit p53 reporter gene activity, which can be blocked by shRNA knock down of p53. Conclusions/Significance: In melanomas expressing high levels of wild type p53 this tumor suppressor is frequently inactivated at transcriptional level.

Published
2009

411. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

Author

Houben, Roland, Becker, Jürgen C, Kappel, Andreas, Terheyden, Patrick, Bröcker, Eva-B, Goetz, Rudolf, and Rapp, Ulf R

Subjects
Research, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, neoplasms, lcsh:RC254-282
Abstract

Background Genes of the Raf family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Recently, it was shown that activating mutations of BRaf are found with high frequency in human melanomas. The Ras family member most often mutated in melanoma is NRas. Methods The constitutive activation of the Ras/Raf signaling pathway suggests an impact on the clinical course of the tumor. To address this notion, we analyzed tumor DNA from 114 primary cutaneous melanomas and of 86 metastatic lesions obtained from 174 patients for mutations in BRaf (exons 15 and 11) and NRas (exons 1 and 2) by direct sequencing of PCR products and correlated these results with the clinical course. Results In 57.5% of the tumors either BRaf or NRas were mutated with a higher incidence in metastatic (66.3%) than in primary lesions (50.9%). Although the majority of BRaf mutations affected codon 599, almost 15% of mutations at this position were different from the well-described exchange from valine to glutamic acid. These mutations (V599R and V599K) also displayed increased kinase and transforming activity. Surprisingly, the additional BRaf variants D593V, G465R and G465E showed a complete loss of activity in the in vitro kinase assay; however, cells overexpressing these mutants displayed increased Erk phosphorylation. The correlation of mutational status and clinical course revealed that the presence of BRaf/NRas mutations in primary tumors did not negatively impact progression free or overall survival. In contrast, however, for metastatic lesions the presence of BRAF/NRAS mutations was associated with a significantly poorer prognosis, i.e. a shortened survival. Conclusion We demonstrate a high – albeit lower than initially anticipated – frequency of activating BRaf mutations in melanoma in the largest series of directly analyzed tumors reported to date. Notably, the clinical course of patients harboring activating BRaf mutations in metastatic melanoma was significantly affected by the presence of a constitutive BRaf activation in these.

Published
2004

416. Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19–IL2 Results in Sustained Clinical and Systemic Immunologic Responses

Author

Weide, Benjamin, primary, Eigentler, Thomas K., additional, Pflugfelder, Annette, additional, Zelba, Henning, additional, Martens, Alexander, additional, Pawelec, Graham, additional, Giovannoni, Leonardo, additional, Ruffini, Pier Adelchi, additional, Elia, Giuliano, additional, Neri, Dario, additional, Gutzmer, Ralf, additional, Becker, Jürgen C., additional, and Garbe, Claus, additional

Published
2014
Full Text
View/download PDF

417. Adjuvant therapy with pegylated interferon alfa-2a (PEG-IFN) versus low-dose interferon alfa-2a (IFN) in patients with malignant melanoma in stages IIa(T3a): IIIb (AJCC 2002)—Decog-trial.

Author

Eigentler, Thomas K., primary, Gutzmer, Ralf, additional, Hauschild, Axel, additional, Kämpgen, Eckhart, additional, Schadendorf, Dirk, additional, Nashan, Dorothee, additional, Hölzle, Erhard, additional, Trefzer, Uwe, additional, Becker, Jürgen C., additional, Sunderkötter, Cord, additional, Moll, Ingrid, additional, Richtig, Erika, additional, Pönitzsch, Iris, additional, Pehamberger, Hubert, additional, Kaufmann, Roland, additional, Pfoehler, Claudia, additional, Vogt, Thomas, additional, Berking, Carola, additional, Praxmarer, Michael, additional, and Garbe, Claus, additional

Published
2014
Full Text
View/download PDF

418. Intralesional treatment of stage III metastatic melanoma patients with L19-IL2: Clinical and systemic immunological responses.

Author

Neri, Dario, primary, Weide, Benjamin, additional, Eigentler, Thomas K., additional, Pflugfelder, Annette, additional, Zelba, Henning, additional, Pawelec, Graham P., additional, Giovannoni, Leonardo, additional, Ruffini, Pier Adelchi, additional, Elia, Giuliano, additional, Gutzmer, Ralf, additional, Becker, Jürgen C., additional, and Garbe, Claus, additional

Published
2014
Full Text
View/download PDF

420. Response to Shuda et al.

Author

Angermeyer, Sabrina, primary, Hesbacher, Sonja, additional, Becker, Jürgen C., additional, Schrama, David, additional, and Houben, Roland, additional

Published
2014
Full Text
View/download PDF

423. p53 Regulation by TRP2 Is Not Pervasive in Melanoma

Author

Houben, Roland, primary, Schmid, Corinna P., additional, Maier, Melissa, additional, Wobser, Marion, additional, Motschenbacher, Stephanie, additional, Becker, Jürgen C., additional, Vetter-Kauczok, Claudia S., additional, Weyandt, Gerhard, additional, Hesbacher, Sonja, additional, and Haferkamp, Sebastian, additional

Published
2014
Full Text
View/download PDF

424. Neoadjuvant Imatinib in Advanced Primary or Locally Recurrent Dermatofibrosarcoma Protuberans: A Multicenter Phase II DeCOG Trial with Long-term Follow-up

Author

Ugurel, Selma, primary, Mentzel, Thomas, additional, Utikal, Jochen, additional, Helmbold, Peter, additional, Mohr, Peter, additional, Pföhler, Claudia, additional, Schiller, Meinhard, additional, Hauschild, Axel, additional, Hein, Rüdiger, additional, Kämpgen, Eckhardt, additional, Kellner, Ivonne, additional, Leverkus, Martin, additional, Becker, Jürgen C., additional, Ströbel, Philip, additional, and Schadendorf, Dirk, additional

Published
2014
Full Text
View/download PDF

426. Modulation of T-cell responses to Murine Melanoma by Targeted-Cytokine Therapy

Author

Becker, Jürgen C.

Abstract

The present thesis describes the characterization of T cell responses to melanoma and its modulation by in situ cytokine therapy. Previous studies have shown that antibody cytokine fusion proteins, designated immunocytokines, achieve high cytokine concentrations in the tumor microenvironment and thereby effectively stimulate cellular immune responses against malignancies. Analysis of the T cell receptor repertoire of tumor infiltrating lymphocytes, as presented here, revealed operative differences in the immunomodulatory capacity of two proinflammatory cytokines, i.e., interleukin 2 and lymphotoxin ɑ, if applied targeted to the tumor site. While interleukin 2 is boosting an already established T cell response and enables the recirculation of clonally expanded T cells, lymphotoxin ɑ's modus operandi is relying on newly recruited T cells. Via induction of a tertiary lymphoid organ at the tumor site lymphotoxin a immunocytokines allow the recruitment, priming, and activation of naïve T cells to harness an effective T cell response against the tumor.

Published
2001
Full Text
View/download PDF

429. Therapie der fortgeschrittenen kutanen T‐Zell‐Lymphome mit nichtpegyliertem liposomalem Doxorubicin – Konsensus der Lymphomgruppe der Arbeitsgemeinschaft Dermatologische Onkologie

Author

Assaf, Chalid, primary, Becker, Jürgen C., additional, Beyer, Marc, additional, Cozzio, Antonio, additional, Dippel, Edgar, additional, Klemke, Claus‐Detlev, additional, Kurschat, Peter, additional, Weichenthal, Michael, additional, and Stadler, Rudolf, additional

Published
2013
Full Text
View/download PDF

432. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial

Author

Duvic, Madeleine, primary, Dummer, Reinhard, additional, Becker, Jürgen C., additional, Poulalhon, Nicolas, additional, Ortiz Romero, Pablo, additional, Grazia Bernengo, Maria, additional, Lebbé, Celeste, additional, Assaf, Chalid, additional, Squier, Margaret, additional, Williams, Denise, additional, Marshood, Miriam, additional, Tai, Feng, additional, and Prince, H. Miles, additional

Published
2013
Full Text
View/download PDF

436. Prospective International Multicenter Phase II Trial of Intravenous Pegylated Liposomal Doxorubicin Monochemotherapy in Patients With Stage IIB, IVA, or IVB Advanced Mycosis Fungoides: Final Results From EORTC 21012

Author

Dummer, Reinhard, primary, Quaglino, Pietro, additional, Becker, Jürgen C., additional, Hasan, Baktiar, additional, Karrasch, Matthias, additional, Whittaker, Sean, additional, Morris, Stephen, additional, Weichenthal, Michael, additional, Stadler, Rudolf, additional, Bagot, Martine, additional, Cozzio, Antonio, additional, Bernengo, Maria G., additional, and Knobler, Robert, additional

Published
2012
Full Text
View/download PDF

438. An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.

Author

Larkin, James M. G., primary, Queirolo, Paola, additional, Arance, Ana M, additional, Brown, Michael Paul, additional, Hauschild, Axel, additional, Del Vecchio, Michele, additional, McArthur, Grant A., additional, Neyns, Bart, additional, Becker, Jürgen C., additional, Hansson, Johan, additional, Hogg, David, additional, Ascierto, Paolo Antonio, additional, Loquai, Carmen, additional, Espinosa, Enrique, additional, Garbe, Claus, additional, Patel, Poulam M, additional, Schachter, Jacob, additional, Mitchell, Lada, additional, Veronese, Maria Luisa, additional, and Blank, Christian U., additional

Published
2012
Full Text
View/download PDF

445. Identification of Epigenetically Regulated Genes Distinguishing Intracranial from Extracranial Melanoma Metastases

Author

Westphal, Dana, Meinhardt, Matthias, Grützmann, Konrad, Schöne, Lisa, Steininger, Julian, Neuhaus, Lena T., Wiegel, Miriam, Schrimpf, Daniel, Aust, Daniela E., Schröck, Evelin, Baretton, Gustavo B., Beissert, Stefan, Juratli, Tareq A., Schackert, Gabriele G., Gravemeyer, Jan, Becker, Jürgen C., von Deimling, Andreas, Koelsche, Christian, Klink, Barbara, Meier, Friedegund, Schulz, Alexander, Muders, Michael H., and Seifert, Michael

Abstract

Despite remarkable advances in treating patients with metastatic melanoma, the management of melanoma brain metastases remains challenging. Recent evidence suggests that epigenetic reprogramming is an important mechanism for the adaptation of melanoma cells to the brain environment. In this study, the methylomes and transcriptomes of a cohort of matched melanoma metastases were evaluated by integrated omics data analysis. The identified 38 candidate genes displayed distinct promoter methylation and corresponding gene expression changes in intracranial compared with that in extracranial metastases. The 11 most promising genes were validated on a protein level in both tumor and surrounding normal tissue using immunohistochemistry. For eight of them—STK10, PDXK, WDR24, CSPP1, NMB, RASL11B, pPRKCZ/PRKCZ, and pGRB10—a significantly different protein expression in intracranial from that in extracranial metastases was confirmed in accordance with the underlying promoter methylation and gene expression changes. The observed changes imply a distinct intracranial phenotype with increased protein kinase B phosphorylation and a higher frequency of proliferating cells. Knock down of PRKCZ or GRB10 altered the expression of phosphorylated protein kinase B and decreased the viability of a brain-specific melanoma cell line. In summary, epigenetically regulated cancer-relevant alterations were identified that provide insights into the molecular mechanisms that discriminate brain metastases from other organ metastases, which could be exploited by targeting the affected signaling pathways.

Published
2023
Full Text
View/download PDF

446. Germline mutations in BAP1 predispose to melanocytic tumors

Author

Wiesner, Thomas, primary, Obenauf, Anna C, additional, Murali, Rajmohan, additional, Fried, Isabella, additional, Griewank, Klaus G, additional, Ulz, Peter, additional, Windpassinger, Christian, additional, Wackernagel, Werner, additional, Loy, Shea, additional, Wolf, Ingrid, additional, Viale, Agnes, additional, Lash, Alex E, additional, Pirun, Mono, additional, Socci, Nicholas D, additional, Rütten, Arno, additional, Palmedo, Gabriele, additional, Abramson, David, additional, Offit, Kenneth, additional, Ott, Arthur, additional, Becker, Jürgen C, additional, Cerroni, Lorenzo, additional, Kutzner, Heinz, additional, Bastian, Boris C, additional, and Speicher, Michael R, additional

Published
2011
Full Text
View/download PDF

447. Merkel Cell Polyomavirus Status Is Not Associated with Clinical Course of Merkel Cell Carcinoma

Author

Schrama, David, primary, Peitsch, Wiebke K., additional, Zapatka, Marc, additional, Kneitz, Hermann, additional, Houben, Roland, additional, Eib, Steffi, additional, Haferkamp, Sebastian, additional, Moore, Patrick S., additional, Shuda, Masahiro, additional, Thompson, John F., additional, Trefzer, Uwe, additional, Pföhler, Claudia, additional, Scolyer, Richard A., additional, and Becker, Jürgen C., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results